0	7	Nuclear	nuclear	JJ
8	14	NF-ATp	NF-ATp	NNP
15	17	is	be	VBZ
18	19	a	a	DT
20	28	hallmark	hallmark	NN
29	31	of	of	IN
32	44	unstimulated	unstimulated	JJ
45	46	B	b	NN
47	52	cells	cell	NNS
53	57	from	from	IN
58	63	B-CLL	B-CLL	NNP
64	72	patients	patient	NNS
72	73	.	.	.

75	76	B	B	NNP
77	88	lymphocytes	lymphocyte	NNS
89	93	from	from	IN
94	97	the	the	DT
98	108	peripheral	peripheral	JJ
109	114	blood	blood	NN
115	117	of	of	IN
118	126	patients	patient	NNS
127	131	with	with	IN
132	139	chronic	chronic	JJ
140	151	lymphocytic	lymphocytic	JJ
152	161	leukaemia	leukaemia	NN
162	163	(	(	(
163	166	CLL	CLL	NNP
166	167	)	)	)
168	172	were	be	VBD
173	181	analysed	analyse	VBN
182	185	for	for	IN
186	189	the	the	DT
190	197	nuclear	nuclear	JJ
198	206	presence	presence	NN
207	210	and	and	CC
211	214	DNA	dna	NN
215	222	binding	binding	NN
223	225	of	of	IN
226	227	a	a	DT
228	233	panel	panel	NN
234	236	of	of	IN
237	250	transcription	transcription	NN
251	258	factors	factor	NNS
259	264	which	which	WDT
265	268	are	be	VBP
269	277	involved	involve	VBN
278	280	in	in	IN
281	284	the	the	DT
285	289	gene	gene	NN
290	297	control	control	NN
298	300	of	of	IN
301	309	lymphoid	lymphoid	JJ
310	315	cells	cell	NNS
315	316	.	.	.

317	320	The	the	DT
321	330	following	follow	VBG
331	344	transcription	transcription	NN
345	352	factors	factor	NNS
353	357	were	be	VBD
358	365	studied	study	VBN
365	366	:	:	:
367	370	the	the	DT
371	378	Octamer	Octamer	NNP
379	386	factors	factor	NNS
387	392	Oct-1	oct-1	NN
393	396	and	and	CC
397	402	Oct-2	oct-2	NN
402	403	,	,	,
404	411	members	member	NNS
412	414	of	of	IN
415	418	the	the	DT
419	423	AP-1	ap-1	NN
424	430	factor	factor	NN
431	437	family	family	NN
437	438	,	,	,
439	444	NF-AT	NF-AT	NNP
445	452	factors	factor	NNS
452	453	,	,	,
454	456	in	in	IN
457	467	particular	particular	JJ
468	474	NF-ATp	nf-atp	NN
474	475	,	,	,
476	479	and	and	CC
480	487	members	member	NNS
488	490	of	of	IN
491	494	the	the	DT
495	504	Rel/NF-kB	Rel/NF-kB	NNP
505	511	family	family	NN
511	512	.	.	.

513	515	We	we	PRP
516	520	show	show	VBP
521	525	that	that	IN
526	529	the	the	DT
530	542	constitutive	constitutive	JJ
543	550	nuclear	nuclear	JJ
551	564	translocation	translocation	NN
565	567	of	of	IN
568	574	NF-ATp	NF-ATp	NNP
574	575	,	,	,
576	577	a	a	DT
578	584	member	member	NN
585	587	of	of	IN
588	591	the	the	DT
592	599	growing	grow	VBG
600	606	family	family	NN
607	609	of	of	IN
610	615	NF-AT	NF-AT	NNP
616	623	factors	factor	NNS
623	624	,	,	,
625	627	is	be	VBZ
628	629	a	a	DT
630	638	hallmark	hallmark	NN
639	641	of	of	IN
642	655	nonstimulated	nonstimulated	JJ
656	657	B	b	NN
658	663	cells	cell	NNS
664	668	from	from	IN
669	672	CLL	CLL	NNP
673	681	patients	patient	NNS
682	686	that	that	WDT
687	700	distinguishes	distinguish	VBZ
701	706	B-CLL	B-CLL	NNP
707	712	cells	cell	NNS
713	717	from	from	IN
718	719	‘	`	``
719	725	normal	normal	JJ
725	726	’	'	''
727	728	B	b	NN
729	740	lymphocytes	lymphocyte	NNS
740	741	.	.	.

742	754	Constitutive	constitutive	JJ
755	762	nuclear	nuclear	JJ
763	773	appearance	appearance	NN
774	777	was	be	VBD
778	782	also	also	RB
783	791	observed	observe	VBN
792	795	for	for	IN
796	806	NF-kB2/p52	nf-kb2/p52	NN
806	807	.	.	.

808	820	Constitutive	constitutive	JJ
821	828	binding	binding	NN
829	831	of	of	IN
832	839	further	further	JJ
840	846	factor	factor	NN
847	855	proteins	protein	NNS
856	858	to	to	TO
859	862	DNA	DNA	NNP
862	863	,	,	,
864	868	such	such	JJ
869	871	as	as	IN
872	876	JunD	JunD	NNP
876	877	,	,	,
878	883	c-Fos	c-fos	NN
884	887	and	and	CC
888	892	FosB	FosB	NNP
892	893	,	,	,
894	897	was	be	VBD
898	906	detected	detect	VBN
907	909	in	in	IN
910	917	several	several	JJ
918	926	patients	patient	NNS
927	934	whereas	whereas	IN
935	938	the	the	DT
939	951	localisation	localisation	NN
952	955	and	and	CC
956	959	DNA	dna	NN
960	967	binding	binding	NN
968	970	of	of	IN
971	976	other	other	JJ
977	984	factors	factor	NNS
985	989	such	such	JJ
990	992	as	as	IN
993	998	c-Jun	c-jun	NN
998	999	,	,	,
1000	1008	RelA/p65	rela/p65	NN
1009	1012	and	and	CC
1013	1018	c-Rel	c-rel	NN
1019	1022	was	be	VBD
1023	1032	unaltered	unaltered	JJ
1032	1033	.	.	.

1034	1036	It	it	PRP
1037	1039	is	be	VBZ
1040	1050	remarkable	remarkable	JJ
1051	1055	that	that	IN
1056	1058	in	in	IN
1059	1064	B-CLL	B-CLL	NNP
1065	1070	cells	cell	NNS
1071	1074	the	the	DT
1075	1082	nuclear	nuclear	JJ
1083	1093	appearance	appearance	NN
1094	1097	and	and	CC
1098	1101	DNA	dna	NN
1102	1109	binding	binding	NN
1110	1112	of	of	IN
1113	1121	specific	specific	JJ
1122	1135	transcription	transcription	NN
1136	1143	factors	factor	NNS
1144	1146	is	be	VBZ
1147	1159	dramatically	dramatically	RB
1160	1168	affected	affect	VBN
1169	1176	whereas	whereas	IN
1177	1182	other	other	JJ
1183	1190	members	member	NNS
1191	1193	of	of	IN
1194	1197	the	the	DT
1198	1202	same	same	JJ
1203	1209	factor	factor	NN
1210	1216	family	family	NN
1217	1225	remained	remain	VBD
1226	1235	unaltered	unaltered	JJ
1236	1238	in	in	IN
1239	1244	these	these	DT
1245	1253	leukemic	leukemic	JJ
1254	1259	cells	cell	NNS
1259	1260	.	.	.

1261	1263	It	it	PRP
1264	1271	remains	remain	VBZ
1272	1274	to	to	TO
1275	1277	be	be	VB
1278	1283	shown	show	VBN
1284	1289	which	which	WDT
1290	1299	molecular	molecular	JJ
1300	1306	events	event	NNS
1307	1311	lead	lead	VBP
1312	1314	to	to	TO
1315	1318	the	the	DT
1319	1327	specific	specific	JJ
1328	1329	‘	`	``
1329	1343	pre-activation	pre-activation	NN
1343	1344	’	'	''
1344	1345	,	,	,
1346	1350	i.e.	i.e.	FW
1351	1363	constitutive	constitutive	JJ
1364	1371	nuclear	nuclear	JJ
1372	1385	translocation	translocation	NN
1386	1389	and	and	CC
1390	1393	DNA	dna	NN
1394	1401	binding	binding	NN
1401	1402	,	,	,
1403	1405	of	of	IN
1406	1411	these	these	DT
1412	1419	members	member	NNS
1420	1422	of	of	IN
1423	1428	NF-AT	NF-AT	NNP
1428	1429	,	,	,
1430	1435	NF-kB	NF-kB	NNP
1436	1439	and	and	CC
1440	1444	AP-1	ap-1	NN
1445	1451	factor	factor	NN
1452	1460	families	family	NNS
1460	1461	.	.	.